These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
83 related articles for article (PubMed ID: 2193013)
1. Treatment of chronic myelogenous leukemia with bone marrow transplantation. Snyder DS; McGlave PB Hematol Oncol Clin North Am; 1990 Jun; 4(3):535-57. PubMed ID: 2193013 [TBL] [Abstract][Full Text] [Related]
2. The evolving role of bone marrow transplantation in the treatment of chronic myelogenous leukemia. Delage R; Ritz J; Anderson KC Hematol Oncol Clin North Am; 1990 Apr; 4(2):369-88. PubMed ID: 2182597 [TBL] [Abstract][Full Text] [Related]
3. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors. Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736 [TBL] [Abstract][Full Text] [Related]
4. Polymerase chain reaction is highly predictive of relapse in patients following T cell-depleted allogeneic bone marrow transplantation for chronic myeloid leukemia. Mackinnon S; Barnett L; Heller G Bone Marrow Transplant; 1996 Apr; 17(4):643-7. PubMed ID: 8722369 [TBL] [Abstract][Full Text] [Related]
5. Bone marrow transplantation for chronic myelogenous leukemia: clinical outcomes. Enright H; Davies S; McGlave P Clin Transpl; 1994; ():283-93. PubMed ID: 7547549 [TBL] [Abstract][Full Text] [Related]
6. Successful unrelated marrow transplantation for patients over the age of 40 with chronic myelogenous leukemia. Drobyski WR; Pelz C; Kabler-Babbitt C; Hessner M; Baxter-Lowe LA; Keever-Taylor CA Biol Blood Marrow Transplant; 1998; 4(1):3-12. PubMed ID: 9701386 [TBL] [Abstract][Full Text] [Related]
7. Bone marrow transplantation for chronic myeloid leukemia (CML) from unrelated and sibling donors: single center experience. Lamparelli T; Van Lint MT; Gualandi F; Occhini D; Barbanti M; Sacchi N; Ficai G; Ghinatti C; Ferrara GB; Delfino L; Pozzi S; Morabito A; Zikos P; Vitale V; Corvo R; Frassoni F; Bacigalupo A Bone Marrow Transplant; 1997 Dec; 20(12):1057-62. PubMed ID: 9466278 [TBL] [Abstract][Full Text] [Related]
8. [Hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia]. Liu QF; Sun J; Zhang Y; Liu XL; Xu D; Xu B; Feng R; Meng FY; Zhou SY Ai Zheng; 2004 Apr; 23(4):426-9. PubMed ID: 15087032 [TBL] [Abstract][Full Text] [Related]
9. Bone marrow transplantation for chronic myelogenous leukemia. Cunningham I Oncology (Williston Park); 1990 Nov; 4(11):101-8; discussion 108, 111. PubMed ID: 2150321 [TBL] [Abstract][Full Text] [Related]
10. Allogeneic cell-mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic bone marrow transplantation for hematological malignancies. Naparstek E; Nagler A; Or R; Kapelushnik J; Slavin S Clin Transpl; 1996; ():281-90. PubMed ID: 9286578 [TBL] [Abstract][Full Text] [Related]
11. European results of matched unrelated donor bone marrow transplantation for chronic myeloid leukemia. Impact of HLA class II matching. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Devergie A; Apperley JF; Labopin M; Madrigal A; Jacobsen N; Carreras E; Prentice HG; Jouet JP; Kolb HJ; Herstenstein B; Bacigalupo A; Evensen SA; Ljungman P; de Witte T; Reiffers J; Nagler A; Clark RE; Goldman JM; Gratwohl A Bone Marrow Transplant; 1997 Jul; 20(1):11-9. PubMed ID: 9232250 [TBL] [Abstract][Full Text] [Related]
12. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. Petersen SL Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527 [TBL] [Abstract][Full Text] [Related]
13. [Indications, technique and risks in bone marrow transplantation in adulthood]. Heyll A; Söhngen D; Minning H; Meckenstock G; Aul C; Schneider W Praxis (Bern 1994); 1996 Mar; 85(12):378-86. PubMed ID: 8643901 [TBL] [Abstract][Full Text] [Related]
14. Transplantation of haematopoietic stem cells derived from cord blood, bone marrow or peripheral blood: a single centre matched-pair analysis in a heterogeneous risk population. Schönberger S; Niehues T; Meisel R; Bernbeck B; Laws HJ; Kögler G; Enzmann J; Wernet P; Göbel U; Dilloo D Klin Padiatr; 2004; 216(6):356-63. PubMed ID: 15565551 [TBL] [Abstract][Full Text] [Related]
15. Long-term results after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase: a report from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. van Rhee F; Szydlo RM; Hermans J; Devergie A; Frassoni F; Arcese W; de Witte T; Kolb HJ; Niederwiser D; Jacobsen N; Gahrton G; Bandini G; Carreras E; Bacigalupo A; Michallet M; Ruutu T; Reiffers J; Goldman JM; Apperley J; Gratwohl A Bone Marrow Transplant; 1997 Oct; 20(7):553-60. PubMed ID: 9337056 [TBL] [Abstract][Full Text] [Related]
16. Detection of minimal residual disease and persistence of host-type hematopoiesis: a study in 28 patients after sex-mismatched, non-T cell-depleted allogeneic bone marrow transplantation for Philadelphia-chromosome positive chronic myelogenous leukemia. Elmaagacli AH; Becks HW; Beelen DW; Stockova J; Bützler R; Opalka B; Schaefer UW Bone Marrow Transplant; 1995 Dec; 16(6):823-9. PubMed ID: 8750276 [TBL] [Abstract][Full Text] [Related]
17. Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes. Slavin S; Naparstek E; Nagler A; Ackerstein A; Kapelushnik J; Or R Exp Hematol; 1995 Dec; 23(14):1553-62. PubMed ID: 8542946 [TBL] [Abstract][Full Text] [Related]
18. Association with the presence of naive T cells in chronic myeloid leukemia patients after allogeneic human stem cell transplantation and the lower incidence of chronic graft-versus host disease and relapse. Wysoczanska B; Bogunia-Kubik K; Dlubek D; Jaskula E; Sok A; Drabczak-Skrzypek D; Sedzimirska M; Lange A Transplant Proc; 2007 Nov; 39(9):2898-901. PubMed ID: 18022011 [TBL] [Abstract][Full Text] [Related]
19. Multicenter prospective study of interferon-alpha and conventional chemotherapy versus bone marrow transplantation for newly diagnosed patients with chronic myelogenous leukemia. Kouseisho Leukemia Study Group. Ohnishi K; Minami S; Ueda T; Nishimura M; Tsubaki K; Takemoto Y; Takeshita A; Sao H; Kageyama S; Ueda R; Ohno R Int J Hematol; 2000 Aug; 72(2):229-36. PubMed ID: 11039674 [TBL] [Abstract][Full Text] [Related]
20. Donor leukocyte infusions for recurrent hematologic malignancies after allogeneic bone marrow transplantation: impact of infused and residual donor T cells. Verdonck LF; Petersen EJ; Lokhorst HM; Nieuwenhuis HK; Dekker AW; Tilanus MG; de Weger RA Bone Marrow Transplant; 1998 Dec; 22(11):1057-63. PubMed ID: 9877267 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]